Skip to content

Matthew Appleton



Appleton Matthew
Matthew Appleton



Matthew is a Corporate/M&A Partner with a particular focus on the Life Sciences and the Consumer & Retail sectors. He has significant experience advising clients on a wide variety of matters, including private M&A, joint ventures, public takeovers, restructurings and listing requirements.

Matthew has specific expertise in highly complex cross-border M&A transactions.  He regularly advises clients on M&A auction processes, executing successful transactions both for sellers and for buyers.

"Pragmatic legal advice tailored to international environment with considerable industry expertise. Matthew Appleton is focusing specifically on what really matters for the business of his client far beyond legal expertise" - Legal 500 UK 2021 (M&A Upper Mid-Market and Premium Deals)


Experience highlights

Related articles

Strips of pharmaceutical pills

News: 24 November 2022

A&O advises KKI on joint venture collaboration agreement with Grünenthal for established medicines portfolio

Allen & Overy’s Healthcare Transactions Team has advised Japan-based global specialty pharmaceutical company Kyowa Kirin International (KKI) on its joint venture collaboration with global…

Read more

News: 24 December 2021

A&O advising Reckitt on the proposed sale of E45

Read more

News: 24 December 2021

A&O advising the Weston family on its sale of Selfridges Group

Read more

Publications: 08 July 2021

Innovation and search for growth spark MedTech rebound

Read more



One Bishops Square
E1 6AD

View office →



Admitted as solicitor, England and Wales, 2009.


BA, Law, Magdalene College, Cambridge University, 2005.

Fraudulent emails

Please note there is a known fraud/scam currently using the Allen & Overy brand and Matthew Appleton's name.

More information on fraud using the Allen & Overy brand can be found here.

Other noteworthy experience 


  • Grünenthal on multiple transactions, including its USD922m acquisition of the prescription products Nexium in Europe and Vimovo worldwide (excluding the U.S. and Japan), its acquisition of the global rights to the migraine medication Zomig for a total consideration of up to USD302m, and its acquisition of the European rights (excluding Spain and the UK) to Crestor (rosuvastatin) and its associated brands for a total consideration of up to USD350 million, each from AstraZeneca.
  • GlaxoSmithKline on its EUR150m investment into, and strategic collaboration with, German biotech company CureVac for the research, development and commercialisation of mRNA-based vaccines and monoclonal antibodies targeting infectious diseases, and its subsequent collaboration with CureVac for the development of next generation mRNA COVID-19 vaccines.
  • GlaxoSmithKline on various disposals of prescription and consumer healthcare products by way of auction.
  • GlaxoSmithKline on the GBP1.35bn disposal of its nutritional drinks brands, Lucozade and Ribena, to Suntory Beverage & Food, the Japanese consumer goods company.
  • Life Healthcare Group Holdings on its GBP600m acquisition of Alliance Medical Group by way of auction.
  • Asahi Group on its USD11.3bn acquisition of Carlton & United Breweries, its EUR7.30bn acquisition of the Central & Eastern European business of SABMiller, and its EUR2.55bn acquisition of Peroni, Grolsch and Meantime, each from AB InBev.
  • Tesco on the GBP181m sale of its Polish business to Salling Group and additional divestments of its Polish store estate.
  • SSL International on its recommended public takeover by Reckitt Benckiser for GBP2.54bn.
  • Tullett Prebon on its GPB1.4bn reverse takeover, carve-out acquisition of ICAP's global hybrid broking and information business and related issuance of consideration shares and readmission to the LSE.
  • TUI AG on its all-share merger with TUI Travel and related admission to the LSE.